Jun 27, 2022 / 08:00AM GMT
Operator
Ladies and gentlemen, welcome to the Lundbeck teleconference headline results from the AAD trial. (Operator Instructions) Today, I am pleased to present Deborah Dunsire, President and CEO; and Johan Luthman, Executive Vice President and Head of Research and Development. Speakers, please begin.
Deborah Dunsire - H. Lundbeck A/S-President&CEO
Thank you, operator, and welcome, everybody, to today's headline results call. We are delighted to be presenting to you the outcome of the third of the Phase III trials with brexpiprazole in agitation in Alzheimer's disease patients. I need to preface this by saying we only just have the data and we only just have the headline results. So we will not be going into great detail on the studies, as we are conducting further analyses. But let me start by saying we have obviously our disclosures that we have forward-looking statements.
So moving on to the next slide. One of the reasons that this is incredibly important is that there is no FDA-approved pharmacological
H Lundbeck A/S and Otsuka Pharmaceutical to Briefly Discuss the Topline Results of Clinical Trial Call Transcript
Jun 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers